In line with the regulatory requirements (CHMP/ EWP/ 191583/ 2005), a formal proof of bioequivalence, evidence of a wide therapeutic experience, and an adequately established benefit/ risk ratio should be demonstrated for new fixed dose combination products claiming substitution indication.